Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Founded in 2020 and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women's cancers including ovarian cancer and breast cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/26/22 | $76,000,000 | Series A |
Alexandria Venture Investments ARCH Venture Partners  Catalio Capital Management Risk and Return | undisclosed |
